Zacks: Analysts Expect Sarepta Therapeutics Inc (SRPT) to Announce -$0.47 Earnings Per Share

Analysts forecast that Sarepta Therapeutics Inc (NASDAQ:SRPT) will announce ($0.47) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Nine analysts have made estimates for Sarepta Therapeutics’ earnings, with estimates ranging from ($1.24) to ($0.21). Sarepta Therapeutics reported earnings of ($1.15) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 59.1%. The firm is scheduled to announce its next earnings results on Wednesday, July 18th.

On average, analysts expect that Sarepta Therapeutics will report full year earnings of ($1.22) per share for the current year, with EPS estimates ranging from ($1.61) to ($0.90). For the next fiscal year, analysts anticipate that the company will report earnings of $0.15 per share, with EPS estimates ranging from ($0.88) to $1.18. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Thursday, May 3rd. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.23). The firm had revenue of $64.60 million for the quarter, compared to analysts’ expectations of $65.31 million. Sarepta Therapeutics had a negative return on equity of 24.68% and a negative net margin of 83.88%. The company’s revenue for the quarter was up 295.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.57) earnings per share.

Several analysts have issued reports on the company. Credit Suisse Group reaffirmed a “hold” rating and set a $81.00 target price on shares of Sarepta Therapeutics in a research report on Monday, March 12th. BTIG Research assumed coverage on Sarepta Therapeutics in a research report on Friday, June 15th. They set a “buy” rating and a $120.00 target price on the stock. Leerink Swann increased their target price on Sarepta Therapeutics from $88.00 to $121.00 and gave the company an “outperform” rating in a research report on Tuesday, May 15th. BidaskClub cut Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 29th. Finally, Goldman Sachs Group increased their target price on Sarepta Therapeutics from $84.00 to $127.00 and gave the company a “buy” rating in a research report on Friday, May 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $126.50.

Shares of Sarepta Therapeutics opened at $135.29 on Friday, according to Marketbeat. The company has a current ratio of 13.37, a quick ratio of 12.28 and a debt-to-equity ratio of 0.55. The firm has a market cap of $8.89 billion, a price-to-earnings ratio of -82.49 and a beta of 1.34. Sarepta Therapeutics has a 12-month low of $32.80 and a 12-month high of $176.50.

In other Sarepta Therapeutics news, Director Richard Barry sold 75,000 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, June 27th. The stock was sold at an average price of $130.34, for a total transaction of $9,775,500.00. Following the completion of the sale, the director now owns 3,170,432 shares of the company’s stock, valued at approximately $413,234,106.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 7.90% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. LPL Financial LLC purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $643,000. TimesSquare Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 3.5% during the 4th quarter. TimesSquare Capital Management LLC now owns 491,250 shares of the biotechnology company’s stock valued at $27,333,000 after buying an additional 16,800 shares during the last quarter. Delek Group Ltd. purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $2,056,000. Xact Kapitalforvaltning AB purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $345,000. Finally, Handelsbanken Fonder AB purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $1,196,000. Institutional investors and hedge funds own 86.27% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply